Vitamins China Monthly Report

In June 2024, the vitamin market heated up, and vitamin prices were generally buoyant, due to the holding of CPHI China 2024 in Shanghai Municipality, as well as major vitamin producers' pricing movements and maintenance season. Market attention focused on vitamin B1, vitamin C, vitamin E, and vitamin D3 this month.

The news of the ban on NMN sales on cross-border e-commerce platforms in China has garnered market attention, prompting several companies involved in NMN industry to respond. Since NMN has not been approved as a drug, health food, food additive, or new food raw material (ingredient) in China, it cannot be produced and sold as food domestically. Consequently, food products containing NMN are often sold through cross-border e-commerce platforms.

Four listed firms, namely Shanghai Haixin Group Co., Ltd., ClouDr Group Limited, Yifan Pharmaceutical Co., Ltd., and Tibet Weixinkang Medicine Co., Ltd. have disclosed updates on their vitamin injection products.

News about several projects has been reported, including: Shaoxing Minsheng Pharmaceutical Co., Ltd.'s "construction project for relocation, upgrading, and aggregation"; Sichuan Neijiang Huixin Pharmaceutical Co., Ltd.'s "construction project for vitamin D series products production lines"; Shangyu NHU Bio-chem Co., Ltd.'s projects; Shandong Tonghui Biotechnology Co., Ltd.'s "project of creating and industrialising feed additive products for pig use"; Bluestar Adisseo Health Nutrition (Nanjing) Co., Ltd.'s 37,000 t/a specialty products feed additives project, etc.

The USD/CNY exchange rate in this Report is USD1.00=CNY7.1086, which was sourced from the People's Bank of China on 3 June, 2024. All the prices mentioned in this Report will include the VAT, unless otherwise specified.